LAG3 and non-small cell lung carcinoma: In lung cancer, the combination of eftilagimod alpha, a soluble LAG-3 protein that mediates antigen-presenting cell and CD8 T-cell activation, with pembrolizumab was tested in PD-L1 unselected metastatic NSCLC in the first-line setting (phase II TACTI-002 trial).